| Income Statement | 2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Loss before income tax provision | -2,622 | 1,481 | -1,575 | -1,580 |
| Income tax expense | 8 | 7 | 6 | 15 |
| Net income (loss) available to common stockholders, basic | - | - | -1,581 | -1,595 |
| Net loss | -2,630 | 1,474 | - | - |
| Earnings per share, basic | -2.25 | 18.98 | -3.11 | -0.06 |
| Earnings per share, diluted | -2.25 | 18.98 | -3.11 | -0.06 |
| Weighted average number of shares outstanding, basic | 1,168,759 | 77,668 | 508,851 | 25,222,443 |
| Weighted average number of shares outstanding, diluted | 1,168,759 | 77,668 | 508,851 | 25,222,443 |
ReShape Lifesciences Inc. (RSLS)
ReShape Lifesciences Inc. (RSLS)